C07K 14/775
Apolipopeptides
C07K14/775 (Apolipopeptides) appears on 586 US grants and 757 published applications in this corpus.
Search patents in C07K- Granted patents
- 586
- Published applications
- 757
- Assignees
- 389
- Inventors
- 1,467
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 3 | 0 |
| 1991 | 2 | 0 |
| 1992 | 12 | 0 |
| 1993 | 6 | 0 |
| 1994 | 4 | 0 |
| 1995 | 10 | 0 |
| 1996 | 13 | 0 |
| 1997 | 15 | 0 |
| 1998 | 27 | 0 |
| 1999 | 24 | 0 |
| 2000 | 21 | 0 |
| 2001 | 9 | 1 |
| 2002 | 9 | 19 |
| 2003 | 14 | 36 |
| 2004 | 11 | 29 |
| 2005 | 7 | 31 |
| 2006 | 7 | 34 |
| 2007 | 23 | 19 |
| 2008 | 14 | 42 |
| 2009 | 25 | 35 |
| 2010 | 15 | 27 |
| 2011 | 22 | 30 |
| 2012 | 17 | 34 |
| 2013 | 22 | 37 |
| 2014 | 26 | 38 |
| 2015 | 30 | 34 |
| 2016 | 19 | 33 |
| 2017 | 23 | 20 |
| 2018 | 15 | 26 |
| 2019 | 17 | 35 |
| 2020 | 19 | 28 |
| 2021 | 16 | 30 |
| 2022 | 20 | 29 |
| 2023 | 13 | 23 |
| 2024 | 20 | 34 |
| 2025 | 23 | 32 |
| 2026 | 9 | 21 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Nanodisc-specific antigen-binding chimeric proteins8 Sep 2026US 12,729,238 B2United Kingdom Research and Innovation
- Peptides for beta-cell survival and insulin production4 Aug 2026US 12,698,319 B2Protean Bio, Inc.
- Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system23 Jun 2026US 12,661,412 B2University of Massachusetts
- Apolipoprotein L1-specific antibodies and methods of use2 Jun 2026US 12,643,945 B2Genentech, Inc.
- Methods for treatment of psoriasis with an anti-oxLDL antibody5 May 2026US 12,616,749 B2Abcentra, LLC
- Modulating apolipoprotein (a) expression8 Oct 2026US 2026/0308584 A1Ionis Pharmaceuticals, Inc.
- Fusion protein comprising apolipoprotein or fragment thereof, and use thereof1 Oct 2026US 2026/0297167 A1Rnagene Inc.
- Class 2, type v crispr systems17 Sep 2026US 2026/0275332 A1Metagenomi Therapeutics, Inc.
- Synthesis and structure of high potency rna therapeutics10 Sep 2026US 2026/0265769 A1Arcturus Therapeutics, Inc.
- Method for testing diseased state of vasculitis or aggravation risk of covid-19, testing kit, companion diagnostic agent, and testing marker27 Aug 2026US 2026/0251661 A1A-CLIP Institute, Co., Ltd.
Most cited
By later US patents
- Composition for introducing nucleic acid complexes into higher eucaryotic cells257US 5,547,932 ABoehringer Ingelheim International GmbH · 1996
- Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders138US 6,004,925 A1999
- Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders138US 6,037,323 A2000
- HDL particles for delivery of nucleic acids136US 8,734,853 B2Board of Regents, The University of Texas System · 2014
- TRPM-2 antisense therapy119US 7,732,422 B2The University of British Columbia · 2010